Search

Study of the Test-retest Reliability of the Neuropsychiatric Fluctuations Scale in Parkinson's Disease

Trial N/A Recruiting Jan. 19, 2025

The Impact TDCS-linked Motor and Cognitive Training Gains in Parkinson's Disease

Trial N/A Active, not recruiting Jan. 16, 2025

The Parkinson's Disease NeuroGenebank at Scripps Clinic Registry

Trial N/A Active, not recruiting Jan. 15, 2025

Development of a Multifunctional Rehabilitation Device for Persons With Parkinson's Disease

Trial N/A Completed Jan. 13, 2025

Neuroprotective Effects of Long-term TaVNS in Early Parkinson's Disease Patients

Trial N/A Recruiting Jan. 13, 2025

Localized Analysis of Normalized Distance From Scalp to Cortex and Personalized Evaluation (LANDSCAPE)

Trial N/A Enrolling by invitation Jan. 13, 2025

Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

Trial Phase 4 Completed Jan. 13, 2025

Comparative Effects of Alexander Techniques and Feldenkrais Method in Parkinson's Disease

Trial N/A Enrolling by invitation Jan. 13, 2025

French Parkinson's Disease Cohort - NS-PARK

Trial N/A Recruiting Jan. 12, 2025

Pilot Study of Open Label Homocysteine Management Therapy in Levodopa-treated Parkinson's Disease

Trial N/A Recruiting Jan. 12, 2025

Saliva and Extracellular Vesicles for Parkinson's Disease

Trial N/A Completed Jan. 12, 2025

Sing for Your Saunter - Dementia Supplement

Trial N/A Completed Jan. 8, 2025

Prodromal Model of Parkinson's Disease Confined to The Peripheral Nervous System

Trial N/A Enrolling by invitation Jan. 7, 2025

Gait Characteristics and Cognitive Evolution in Parkinson Disease

Trial N/A Completed Jan. 7, 2025

Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease

Trial Phase 2 Withdrawn Jan. 6, 2025

Exploring the Relationship Between L-dopa Responsiveness and Small Intestinal Microbiome in Parkinson's Disease

Trial N/A Not yet recruiting Jan. 6, 2025

A Study of Efficacy and Safety of Idebenone Vs. Placebo in Prodromal Parkinson Disease

Trial Phase 2 Withdrawn Jan. 6, 2025

Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

Trial N/A Not yet recruiting Dec. 31, 2024

Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease

Trial Phase 2 Completed Dec. 31, 2024

Balance Confidence and Kinesiophobia in Parkinson's Disease

Trial N/A Recruiting Dec. 29, 2024